Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
INCY(NASDAQ:INCY) WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the EADV 2025 Congress
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
INCY(NASDAQ:INCY) WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #HSTRUTHS--Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCYWILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
INCYWILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
Incyte to Present at Upcoming Investor Conferences
INCYWILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
INCYWILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCYWILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCYWILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCYWILMINGTON, Del.--(BUSINESS WIRE)--Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
Specialised Therapeutics Expands Existing Supply And Distribution Agreement With Incyte Biosciences To Launch, Distribute Two Additional Medicines From Oncology Portfolio In Australia, New Zealand And Singapore
INCYWhere Incyte Stands With Analysts
INCYUBS Maintains Neutral on Incyte, Maintains $61 Price Target
INCYIncyte To Present New Data From Across Hematology/Oncology Portfolio At 2025 EHA Congress, Including Late-Breaking Data For First In Class, Mutcalr-Directed Monoclonal Antibody, INCA033989
INCYTruist Securities Maintains Hold on Incyte, Raises Price Target to $73
INCYIncyte Announces FDA Approval Of Zynyz Making It First And Only Approved First-Line Treatment For Advanced Anal Cancer Patients In US
INCYIncyte And Novartis Settle Royalty Dispute With $280M Payment And 50% Reduction In Future JAKAFI U.S. Royalties, Resolving Litigation Over 2009 Collaboration Agreement And Releasing $242.2M In Accrued Liabilities
INCY9 Analysts Have This To Say About Incyte
INCYWells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $59
INCYRBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $67
INCYIncyte Sees 2025 Jakafi Net Product Revenues $2.925B-$2.975B (Prior $2.95B-$3B)
INCYIncyte Q1 Adj. EPS $1.16 Beats $1.03 Estimate, Sales $1.05B Beat $995.43M Estimate
INCYIncyte Announces IT Will Present New Early-Stage Data From Its Oncology Portfolio At American Association Of Cancer Research Annual Meeting 2025 In Chicago, IL, From April 25–30
INCYJP Morgan Maintains Neutral on Incyte, Lowers Price Target to $68
INCYMorgan Stanley Maintains Equal-Weight on Incyte, Lowers Price Target to $65
INCYThis PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
INCYTruist Securities Maintains Hold on Incyte, Lowers Price Target to $72
INCYGuggenheim Downgrades Incyte to Neutral, Maintains Price Target to $92
INCYWilliam Blair Downgrades Incyte to Market Perform
INCYIncyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
INCYIncyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.
Incyte Announced Topline Results From Its Phase 3 STOP-HS Clinical Trial Program Of Povorcitinib For Severe Hidradenitis Suppurativa, Both STOP-HS1 And STOP-HS2 Studies Met Their Primary Endpoint At Both Tested Doses
INCYIncyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
INCYCitizens Capital Markets Reiterates Market Perform on Incyteto Market Perform
INCYEli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
INCYEli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks.
Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
INCYIncyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary endpoint fell short.
Reported Saturday, Lilly And Incyte Present Late-Breaking Phase 3 Data Showing Baricitinib Significantly Improves Scalp, Eyebrow, And Eyelash Regrowth In Teens With AA
INCYIncyte And Genesis Therapeutics Enter Into Strategic AI-Focused Research Collaboration
INCYWatching Incyte Shares, Hearing M&A Blog Mentions Merck As Potential Buyer
INCYIncyte, Syndax Announce FDA Approval Of Niktimvo 9 mg And 22 mg Vial Sizes; US Launch Expected In Early February
INCYJMP Securities Reiterates Market Perform on Incyteto Market Perform
INCYIncyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
INCYIncyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets.
Cantor Fitzgerald Reiterates Neutral on Incyteto Neutral
INCYThe Analyst Verdict: Incyte In The Eyes Of 15 Experts
INCYWells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $70
INCYIncyte Shares Resume Trade
INCYWatching Incyte; Sky News City Editor Mark Kleinman Posts On X Merck Is The Latest Industry Giant To Be Linked To A Takeover Bid For Incyte, With Which It Collaborates On Several Drug Development Projects.
INCYIncyte Shares Halted On Circuit Breaker To The Upside, Stock Now Down - 9.67%
INCYWhat's Going On With Incyte Shares Tuesday?
INCYIncyte stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not support further development.
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
INCYIncyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations.
RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $74
INCYCantor Fitzgerald Reiterates Neutral on Incyte
INCY